

ICMJE DISCLOSURE FORM

Date: 23/01/2023
 Your Name: Mark Kris
 Manuscript Title: Adjuvant therapies in stage I–III EGFR-mutated lung cancer: current and future perspectives
 Manuscript number (if known): TLCR-22-723

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	AstraZeneca	AstraZeneca provided funding for medical writing support of this review, in accordance with Good Publications Practice (GPP) guidelines (http://www.ismpp.org/gpp-2022).
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	The National Cancer Institute (USA)	
3	Royalties or licenses		

4	Consulting fees	AstraZeneca	
		Janssen	
		Novartis	
		Sanofi	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	AstraZeneca	Honoraria
		MJH Holdings	Honoraria
		WebMD	Honoraria
		i3 Health	Honoraria
		Dana Farber	Honoraria
		Shanghai Supertech Information	Honoraria
		Pfizer	Honoraria
		Ideology health	Honoraria
		Yale University	Honoraria
		Bebef.DeSenhoras Hospital	Honoraria
		Nexus Health Media	Honoraria
		Daiichi-Sankyo	Honoraria
		JJR Solutions	Honoraria
		Continuing Education Alliance	Honoraria
		British Columbia Cancer	Honoraria
		PER	Honoraria
		Intellisphere, LLC	Honoraria
		University of Toronto	Honoraria
		PHSA Corporation	Honoraria
6	Payment for expert testimony		
7	Support for attending meetings and/or travel		
8	Patents planned, issued or pending		
9	Participation on a Data Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		
13			

Other financial or non-financial interests		

Please summarize the above conflict of interest in the following box:

Dr Kris reports honoraria from AstraZeneca, MJH Holdings, WebMD, i3 Health, Dana Farber, Shanghai Supertech Information, Pfizer, Ideology health, Yale University, Bebef. DeSenhoras Hospital, Nexus Health Media, Daiichi-Sankyo, JJR Solutions, Continuing Education Alliance, British Columbia Cancer, PER, Intellisphere, LLC, University of Toronto, PHSA Corporation; consulting fees from AstraZeneca, Pfizer, Janssen, Novartis, Sanofi and grants or funds from The National Cancer Institute (USA).

Please place an “X” next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: _____ 23/01/2023 _____
 Your Name: _____ Tetsuya Mitsudomi _____
 Manuscript Title: _____ Adjuvant therapies in stage I–III EGFR-mutated lung cancer: current and future perspectives _____
 Manuscript number (if known): _____ TLCR-22-723 _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	AstraZeneca	AstraZeneca provided funding for medical writing support of this review, in accordance with Good Publications Practice (GPP) guidelines (http://www.ismpp.org/gpp-2022).
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Boehringer Ingelheim	
		MSD	
		ONO	
		Chugai	
		Bridge Biopharm	
3	Royalties or licenses		

4	Consulting fees	AstraZeneca Novartis Janssen	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	AstraZeneca Boehringer Ingelheim Roche Pfizer MSD ONO BMS Taiho Chugai Eli-Lilly Novartis Amgen Takeda Merck Biopharama	
6	Payment for expert testimony		
7	Support for attending meetings and/or travel		
8	Patents planned, issued or pending		
9	Participation on a Data Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	International association for the study of lung cancer	Board of directors
11	Stock or stock options		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		
13	Other financial or non-financial interests		

Please summarize the above conflict of interest in the following box:

Prof Mitsudomi reports honoraria from AstraZeneca, Boehringer Ingelheim, Roche, Pfizer, MSD, ONO, BMS, Taiho, Chugai, Eli-Lilly, Novartis, Amgen, Takeda, Merck Biopharama; consulting fees from AstraZeneca, Boehringer Ingelheim, Roche, Pfizer, MSD, ONO, BMS, Taiho, Chugai, Eli-Lilly, Novartis, Amgen, Takeda, Merck Biopharama AstraZeneca, Novartis, Janssen; grants or funds from Boehringer Ingelheim, MSD, ONO, Chugai, Bridge Biopharam; and is on the Board of directors for International association for the study of lung cancer.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 23/01/2023
 Your Name: Solange Peters
 Manuscript Title: Adjuvant therapies in stage I–III EGFR-mutated lung cancer: current and future perspectives
 Manuscript number (if known): TLCR-22-723

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	AstraZeneca	AstraZeneca provided funding for medical writing support of this review, in accordance with Good Publications Practice (GPP) guidelines (http://www.ismpp.org/gpp-2022).
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Amgen, AstraZeneca, Beigene, Bristol-Myers Squibb, GSK, Merck Sharp and Dohme, Roche/Genentech.	Sponsored as Principal investigator in trials (institutional financial support for clinical trials) – honoraria (all fees to institution)
3	Royalties or licenses		
4	Consulting fees	AbbVie, Amgen, Arcus, AstraZeneca, Bayer, Beigene, Biocartis, BioInvent, Blueprint Medicines, Boehringer	Consultation / Advisory role: honoraria (all fees to institution)

		<p>Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, F-Star, Fishawack, Foundation Medicine, Genzyme, Gilead, GSK, Illumina, Imedex, IQVIA, Incyte, iTeos, Janssen, Medscape, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Novocure, OncologyEducation, Pharma Mar, Phosplatin Therapeutics, PER, Pfizer, PRIME, Regeneron, RMEI, Roche/Genentech, RTP, Sanofi, Seattle Genetics, Takeda, Vaccibody.</p>	
5	<p>Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events</p>	<p>AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, ecancer, Eli Lilly, Foundation Medicine, Illumina, Imedex, Medscape, Merck Sharp and Dohme, Mirati, Novartis, PER, Pfizer, Prime, Roche/Genentech, RTP, Sanofi, Takeda.</p>	<p>Talk in a company's organized public event: honoraria (all fees to institution)</p>
6	<p>Payment for expert testimony</p>		
7	<p>Support for attending meetings and/or travel</p>		
8	<p>Patents planned, issued or pending</p>		
9	<p>Participation on a Data Safety Monitoring Board or Advisory Board</p>		
10	<p>Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid</p>		
11	<p>Stock or stock options</p>		
12	<p>Receipt of equipment, materials, drugs, medical writing, gifts or other services</p>		
13	<p>Other financial or non-financial interests</p>		

Please summarize the above conflict of interest in the following box:

Prof Peters reports receiving education grants, provided consultation, attended advisory boards and/or provided lectures for the following organizations, honoraria (all fees to institution): Consultation / Advisory role: AbbVie, Amgen, Arcus, AstraZeneca, Bayer, Beigene, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, F-Star, Fishawack, Foundation Medicine, Genzyme, Gilead, GSK, Illumina, Imedex, IQVIA, Incyte, iTeos, Janssen, Medscape, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Novocure, OncologyEducation, Pharma Mar, Phosplatin Therapeutics, PER, Pfizer, PRIME, Regeneron, RMEI, Roche/Genentech, RTP, Sanofi, Seattle Genetics, Takeda, Vaccibody; Talk in a company's organized public event: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, ecancer, Eli Lilly, Foundation Medicine, Illumina, Imedex, Medscape, Merck Sharp and Dohme, Mirati, Novartis, PER, Pfizer, Prime, Roche/Genentech, RTP, Sanofi, Takeda; Receipt of grants/research supports: Principal investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Beigene, Bristol-Myers Squibb, GSK, Merck Sharp and Dohme, Roche/Genentech.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.